Jushi Holdings Inc. (OTCQX: JUSHF) recently announced it has signed an agreement to buy 100% equity interest of an entity operating a recreational and medical dispensary under the name The Apothecarium in Las Vegas, Nevada. The purchase price was not disclosed.
This acquisition together with the April 2021 purchase of Franklin Bioscience NV, LLC, enables Jushi to become vertically integrated in Nevada.
Year to date, the company’s stock lost 30.30%.
Viridian Capital Advisors’ Jonathan DeCourcey initiated coverage of Jushi Holdings with a Buy rating and $5.25 price target.
Jushi built itself into a leading multi-state operator via the purchases and growth of assets in California, Nevada, Ohio, Illinois, Massachusetts, Pennsylvania, and Virginia, with the last four ones being the most important markets for the company. The analyst projects for Pennsylvania to legalize adult-use cannabis the following year and start the sales in 2023.
DeCourcey highlighted …